HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.

Abstract
This is a synopsis of presentations made at the American College of Cardiology (ACC) in 2001 summarising recent research developments relating to heart failure. Clinical studies of particular interest to physicians with an interest in heart failure and its prevention are reviewed. The COPERNICUS trial lends further support to the use of the beta-blocker, carvedilol, in severe heart failure and the CAPRICORN trial to its use in patients with post-infarction left ventricular systolic dysfunction. The MIRACLE study reinforces the evidence from three smaller trials that cardiac resynchronisation therapy is an effective treatment for the relief of symptoms in patients with severe heart failure and cardiac dyssynchrony. The STAF trial casts further doubt on the wisdom of cardioversion as a routine strategy for the management of chronic atrial fibrillation. The RITZ-2 trial suggests that an intravenous, non-selective endothelin antagonist is effective in improving haemodynamics and symptoms and possibly in reducing morbidity in severe heart failure. Observational studies in heart failure suggest that a moderate excess of body fat and elevated blood cholesterol may be desirable in patients with heart failure, challenging the current non-evidenced-based vogue for cholesterol lowering therapy in heart failure. The RENAISSANCE and RECOVER outcome studies of etanercept, a tumour necrosis factor (TNF) receptor analogue that blocks the effect of TNF, were stopped because of lack of evidence of benefit shortly after the ACC.
AuthorsA Louis, J G Cleland, S Crabbe, S Ford, S Thackray, T Houghton, A Clark
JournalEuropean journal of heart failure (Eur J Heart Fail) Vol. 3 Issue 3 Pg. 381-7 (Jun 2001) ISSN: 1388-9842 [Print] England
PMID11378012 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Review)
Chemical References
  • Adrenergic beta-Antagonists
  • Carbazoles
  • Carboxylic Acids
  • Cytokines
  • Endothelins
  • Indans
  • Propanolamines
  • Pyridines
  • Tetrazoles
  • Vasodilator Agents
  • Carvedilol
  • tezosentan
  • Cholesterol
  • enrasentan
Topics
  • Adrenergic beta-Antagonists (therapeutic use)
  • Atrial Fibrillation (complications)
  • Cachexia (complications, drug therapy)
  • Carbazoles (therapeutic use)
  • Carboxylic Acids (therapeutic use)
  • Carvedilol
  • Cholesterol (blood)
  • Cytokines (antagonists & inhibitors)
  • Endothelins (antagonists & inhibitors)
  • Heart Failure (drug therapy, etiology)
  • Humans
  • Indans (therapeutic use)
  • Injections, Intravenous
  • Myocardial Infarction (complications, drug therapy)
  • Propanolamines (therapeutic use)
  • Pyridines (administration & dosage)
  • Tetrazoles (administration & dosage)
  • United States
  • Vasodilator Agents (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: